What question did this study set out to answer?

To determine the stage-dependent therapeutic effects of interleukin-2 administration on viral replication, immune cell activity, and cardiac pathology in mice infected with coxsackievirus B3.

June 1, 1994CirculationOpen Access

Cytokine and murine coxsackievirus B3 myocarditis. Interleukin-2 suppressed myocarditis in the acute stage but enhanced the condition in the subsequent stage.

View Full Paper

Ask AI

Bookmark

Why the study?

Does recombinant human IL-2 improve survival and reduce cardiac pathology in murine coxsackievirus B3 myocarditis?

Population

BALB/c mice and athymic nude mice infected with coxsackievirus B3 (CB3)

Comparison

Recombinant human IL-2 administered… vs Infected animals that did not receive IL-2

Design

Preclinical

Follow-up

14 days

Authors

CKChiharu KishimotoKyoto University YKYoshito KurokiKyorin University YHYuji HiraokaJichi Medical University

Discussion

Member takes

Implication

Timing of IL-2 determines outcomes in murine viral myocarditis; leaves open human translation and optimal immunomodulation strategies.

Key Points

To determine the stage-dependent therapeutic effects of interleukin-2 administration on viral replication, immune cell activity, and cardiac pathology in mice infected with coxsackievirus B3.
Administered recombinant human interleukin-2 (5 x 10^4 U subcutaneously) to BALB/c mice either early (days 0–7, n=30) or late (days 7–14, n=30) after coxsackievirus B3 infection, alongside untreated control groups.
Measured splenic natural killer cell cytotoxic activity via chromium-51 release assays and assessed myocardial lymphocyte subsets and histopathology on days 7 and 10.
Evaluated late interleukin-2 administration in coxsackievirus B3-infected athymic nude mice to assess T-cell dependence.
Early interleukin-2 treatment increased 7-day survival, reduced myocardial viral titers, decreased inflammatory cell infiltration and myocardial necrosis, and increased splenic natural killer cell activity.
Late interleukin-2 treatment decreased 14-day survival, worsened myocardial inflammatory infiltration and necrosis, and increased myocardial T-cell infiltration without significantly altering natural killer cell activity.
Late administration of interleukin-2 in infected athymic nude mice produced no effect on disease outcome, confirming that late-stage exacerbation is mediated by T cells.

Structured PICO

Does recombinant human IL-2 improve survival and reduce cardiac pathology in murine coxsackievirus B3 myocarditis?

Population

BALB/c mice and athymic nude mice infected with coxsackievirus B3 (CB3)

Intervention

Recombinant human IL-2 (5 x 10^4 U) administered subcutaneously early (days 0 to 7) or late (days 7 to 14) after infection

Comparator

Infected animals that did not receive IL-2

Outcome

Survival, myocardial virus titers, inflammatory cell infiltration, severity of necrosis, splenic natural killer (NK) cell activity, and distribution of myocardial lymphocyte subsetssurrogate

IL-2 has a biphasic effect in murine coxsackievirus B3 myocarditis, limiting pathology when given early but exacerbating it when given late.

Cite This Study

Kishimoto et al. (1994) studied this question.

synapsesocial.com/papers/6a11d8f68095bbd48eb4cf43 https://doi.org/10.1161/01.cir.89.6.2836

Topics

Myocarditis

View Full Paper

Ask AI

Bookmark

Cytokine and murine coxsackievirus B3 myocarditis. Interleukin-2 suppressed myocarditis in the acute stage but enhanced the condition in the subsequent stage.

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Cytokine and murine coxsackievirus B3 myocarditis. Interleukin-2 suppressed myocarditis in the acute stage but enhanced the condition in the subsequent stage.

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider